PET显像剂18F-FLT在脑胶质瘤中的研究进展

Progress in research of PET imaging agent 18F-FLT in glioma

脑胶质瘤是最常见的颅内肿瘤,占脑肿瘤的40%~55%,其诊断时间直接影响患者的预后。近年来,PET显像剂在脑胶质瘤中的应用得到了快速发展。18F-脱氧胸腺嘧啶核苷(18F-FLT)就是其中之一。18F-FLT是经过放射性核素标记的胸腺嘧啶的类似物,是较常见的正电子显像剂,用于评估细胞的增殖情况,它能在肿瘤治疗前、治疗中及治疗后提供其他影像学检查和显像剂不能提供的信息。笔者主要对目前脑胶质瘤显像剂的研究现状,18F-FLT的显像机制、18F-FLT对脑胶质瘤的诊断、分级、鉴别复发与坏死、疗效评估和预后判断以及18F-FLT与Ki-67的关系等方面进行了阐述。

Glioma is the most common intracranial tumor, accounting for 40%–55% of brain tumor cases. The time of diagnosis affects the prognosis of patients. The application of PET imaging agents, which is a noninvasive method of diagnosis, to glioma has increased rapidly in recent years. 18F fluorothymidine (18F-FLT) is a common PET imaging agent, which is a radioactive thymidine analog and is used to evaluate cell proliferation. This imaging agent can provide more information than that from other imaging examinations and agents during and after the treatment of glioma. In this review, we mainly discuss the present research status of glioma imaging agents in the brain, including the 18F-FLT imaging mechanism;the diagnosis, classification, and identification of recurrence and necrosis;the curative effect evaluation and prognosis of glioma from 18F-FLT;and the relationship between 18F-FLT and Ki-67.